Delaware
|
36-1823834
|
|
(State or other jurisdiction of
|
(IRS Employer
|
|
incorporation)
|
Identification No.)
|
STEPAN COMPANY
|
||||||||
Date: February 19, 2013
|
By:
|
/s/ Kathleen Sherlock
|
||||||
Kathleen Sherlock
|
||||||||
Assistant Secretary
|
||||||||
Exhibit No.
|
Description
|
|
EX-99.1
|
Press Release of Stepan Company dated February 19, 2013
|
Exhibit 99.1 | ||||||
FOR RELEASE: | IMMEDIATELY | CONTACT: | JAMES E. HURLBUTT | |||
847-446-7500 |
STEPAN REPORTS FIFTH CONSECUTIVE YEAR OF RECORD EARNINGS FOURTH QUARTER NET INCOME UP 17 PERCENT
FULL YEAR NET INCOME UP 10 PERCENT
NORTHFIELD, Illinois, February 19, 2013 -- Stepan Company (NYSE: SCL) today reported its fifth consecutive record net income year generating a five year compound growth rate of 39 percent.
SUMMARY | ||||||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||||||
December 31 | December 31 | |||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||
($ in thousands) | % | % | ||||||||||||||||||
2012 | 2011 | Change | 2012 | 2011 | Change | |||||||||||||||
Net Sales | $ 427,259 | $ 444,170 | - 4 | $ 1,803,737 | $ 1,843,092 | - 2 | ||||||||||||||
Net Income | $ | 15,439 | $ | 13,179 | + 17 | $ | 79,396 | $ | 71,976 | + 10 | ||||||||||
Net Income Excluding | ||||||||||||||||||||
Deferred Compensation* | $ | 18,010 | $ | 15,371 | + 17 | $ | 84,834 | $ | 72,900 | + 16 | ||||||||||
Earnings per Diluted Share | $0.68 | $0.59 | + 15 | $3.49 | $3.21 | + 9 | ||||||||||||||
Earnings per Diluted Share | ||||||||||||||||||||
Excluding Deferred | ||||||||||||||||||||
Compensation | $0.79 | $0.68 | + 16 | $3.73 | $3.25 | + 15 | ||||||||||||||
* See Table II for a discussion of deferred compensation plan accounting. |
FOURTH QUARTER AND FULL YEAR RESULTS | ||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||
December 31 | December 31 | |||||||||||
|
|
|
|
|
|
|||||||
($ in thousands) | % | % | ||||||||||
2012 | 2011 | Change | 2012 | 2011 | Change | |||||||
Net Sales | ||||||||||||
Surfactants | $310,454 | $331,430 | - 6 | $1,305,800 | $1,361,956 | - 4 | ||||||
Polymers | 103,116 | 94,201 | + 9 | 423,959 | 421,515 | + 1 | ||||||
Specialty Products | 13,689 | 18,539 | - 26 | 73,978 | 59,621 | + 24 | ||||||
|
|
|||||||||||
Total Net Sales | $427,259 | $444,170 | - 4 | $1,803,737 | $1,843,092 | - 2 |
The decrease in sales was due to lower selling prices and foreign translation, partially offset by higher volume.
Percentage Change in Net Sales | ||||||||
|
||||||||
Three Months Ended | Twelve Months Ended | |||||||
December 31, 2012 | December 31, 2011 | |||||||
Volume | + | 3 | + | 2 | ||||
Selling Price | - | 6 | - | 2 | ||||
Foreign Translation | - | 1 | - | 2 | ||||
Total | - | 4 | - | 2 |
2
Gross profit increased by 17 percent to $70.1 million for the quarter and rose 14 percent to $291.6 million for the year.
3
OPERATING EXPENSES | ||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||
December 31 | December 31 | |||||||||||
|
|
|
|
|
|
|
||||||
($ in thousands) | % | % | ||||||||||
2012 | 2011 | Change | 2012 | 2011 | Change | |||||||
Selling | $14,381 | $11,921 | + 21 | $53,145 | $45,807 | + 16 | ||||||
Administrative General | 14,562 | 13,263 | + 10 | 53,728 | 49,237 | + 9 | ||||||
Administrative Deferred | ||||||||||||
Compensation Plan | ||||||||||||
Expense * | 3,990 | 4,240 | - 6 | 10,251 | 1,529 | NM | ||||||
Research, development | ||||||||||||
and technical service | 12,583 | 9,554 | + 32 | 45,713 | 40,524 | + 13 | ||||||
|
||||||||||||
Total | $45,516 | $38,978 | + 17 | $162,837 | $137,097 | + 19 | ||||||
* See Table II for a discussion of deferred compensation plan accounting. |
Increased headcount to support growth initiatives contributed to the full year increase in all categories. Also contributing to the higher expense in all categories was the effect of higher performance based compensation expense due to the strong operating results for the Company. The higher fourth quarter research expenses include higher product registration costs in Europe.
BALANCE SHEET |
The Companys net debt level declined by $3.0 million for the quarter and $9.9 million for the year:
12/31/12 | 9/30/12 | 6/30/12 | 3/31/12 | 12/31/11 | ||||||
Net Debt | ||||||||||
Total Debt | $182.4 | $188.2 | $195.3 | $201.0 | $199.5 | |||||
Cash | 76.9 | 79.7 | 69.5 | 64.6 | 84.1 | |||||
Net Debt | $105.5 | $108.5 | $125.8 | $136.4 | $115.4 | |||||
Equity | 480.9 | 467.8 | 443.2 | 434.7 | 405.5 | |||||
Net Debt + Equity | $586.4 | $576.3 | $569.0 | $571.1 | $520.9 | |||||
Ratio of Net Debt to | ||||||||||
Net Debt + Equity | 18.0% | 18.8% | 22.1% | 23.9% | 22.2% |
4
The Companys stockholders equity has grown over the last three years to $479 million from $289 million. The health of the Companys balance sheet remains strong and will allow us to continue investment in growth opportunities.
The fourth quarter decrease in net debt was attributable to lower seasonal working capital requirements. The full year decrease in net debt was due to the deflationary impact of lower commodity raw material costs on receivables, partially offset by higher quantities of inventory on hand for our Singapore plant start-up. Capital expenditures for the quarter and year-to-date periods were $22.3 million and $83.2 million, respectively.
OUTLOOK |
The investments made over the last several years helped the Company deliver a 16% increase in full year net income, excluding deferred compensation. In 2013 we will continue to pursue geographic expansion and higher value opportunities within all three of our business segments. Our strategy and ability to execute provide us with the opportunity for continued earning growth in 2013.
Surfactants expects to continue to derive more of its profits from higher value added products in the agricultural, oilfield and household and industrial cleaning markets. Demand for crop protection chemicals is expected to remain strong in 2013. We are positioned for further profit growth in Brazil. Our Singapore plant is now operational and should contribute modestly to earnings in 2013 and more significantly beyond that as we diversify production at the site.
Polymers should experience continued growth from polyol used in energy saving rigid foam insulation. Recent demand growth has largely come from greater insulation levels for replacement roofing. A recovering economy would stimulate the commercial construction market and eventually restore that demand. Our polymers segment is expected to face higher costs to operate in China in 2013 and 2014 as the government is requiring that we relocate our plant to a new industrial zone. We plan to supply our Asian customers with product toll produced by another chemical plant in China or imported from other Stepan production sites. We anticipate the higher costs of operating in China will limit polymer earnings growth in 2013.
In 2012 we achieved our fifth consecutive record income year and our forty-fifth consecutive annual dividend increase. Our balance sheet is strong and we intend to leverage that strength to make investments that will accelerate our growth and deliver value to our shareholders, said F. Quinn Stepan, Jr., President and Chief Executive Officer.
5
CONFERENCE CALL |
Stepan Company will host a conference call to discuss the fourth quarter and year end results at 2 p.m. ET (1:00 p.m. CT) on February 20, 2013. Telephone access to the live conference call will be available by dialing +1 (800) 272-5460. To listen to a live webcast of this call, please go to our Internet website at: www.stepan.com, click on investor relations, next click on conference calls and follow the directions on the screen.
ABOUT STEPAN COMPANY |
Stepan Company, headquartered in Northfield, Illinois, is a leading producer of specialty and intermediate chemicals used in household, industrial, personal care, agricultural, food and insulation related products. The common and the convertible preferred stocks are traded on the New York and Chicago Stock Exchanges under the symbols SCL and SCLPR.
For more information about Stepan Company, please visit the Company online at www.stepan.com.
# # # # table follows |
Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Stepan Companys Form 10-K, Form 8-K and Form 10-Q reports and exhibits to those reports, and include (but are not limited to), prospects for our foreign operations, foreign currency fluctuations, certain global and regional economic conditions, the probability of future acquisitions and the uncertainties related to the integration of acquired businesses, the probability of new products, the loss of one or more key customer or supplier relationships, the costs and other effects of governmental regulation and legal and administrative proceedings, including the expenditures necessary to address and resolve environmental claims and proceedings, and general economic conditions. These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
6
Table I | ||||||||||||||||
STEPAN COMPANY | ||||||||||||||||
Statements of Income | ||||||||||||||||
For the Three and Twelve Months Ended December 31, 2012 and 2011 | ||||||||||||||||
(Unaudited 000s Omitted) | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31 | December 31 | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
% | % | |||||||||||||||
2012 | 2011 | Change | 2012 | 2011 | Change | |||||||||||
Net Sales | $427,259 | $444,170 | - | 4 | $1,803,737 | $1,843,092 | - | 2 | ||||||||
Cost of Sales | 357,139 | 384,068 | - | 7 | 1,512,184 | 1,587,539 | - | 5 | ||||||||
|
|
|
|
|||||||||||||
Gross Profit | 70,120 | 60,102 | + | 17 | 291,553 | 255,553 | + | 14 | ||||||||
Operating Expenses: | ||||||||||||||||
Selling | 14,381 | 11,921 | + | 21 | 53,145 | 45,807 | + | 16 | ||||||||
Administrative | 18,552 | 17,503 | + | 6 | 63,979 | 50,766 | + | 26 | ||||||||
Research, Development | ||||||||||||||||
and Technical Services | 12,583 | 9,554 | + | 32 | 45,713 | 40,524 | + | 13 | ||||||||
|
|
|
||||||||||||||
45,516 | 38,978 | + | 17 | 162,837 | 137,097 | + | 19 | |||||||||
Operating Income | 24,604 | 21,124 | + | 16 | 128,716 | 118,456 | + | 9 | ||||||||
Other Income (Expense): | ||||||||||||||||
Interest, Net | (2,225) | (2,582) | - | 14 | (9,599) | (9,095) | + | 6 | ||||||||
Loss from Equity | ||||||||||||||||
in Joint Ventures | (907) | (956) | - | 5 | (4,724) | (3,616) | + | 31 | ||||||||
Other, Net | (223) | 612 | NM | 1,329 | (851) | NM | ||||||||||
|
|
|
||||||||||||||
(3,355) | (2,926) | + | 15 | (12,994) | (13,562) | - | 4 | |||||||||
Income Before Income Taxes | 21,249 | 18,198 | + | 17 | 115,722 | 104,894 | + | 10 | ||||||||
Provision for Income Taxes | 5,756 | 4,649 | + | 24 | 36,035 | 32,292 | + | 12 | ||||||||
|
|
|
|
|||||||||||||
Net Income | 15,493 | 13,549 | + | 14 | 79,687 | 72,602 | + | 10 | ||||||||
Net Income Attributable to | ||||||||||||||||
Noncontrolling Interests | (54) | (370) | - | 85 | (291) | (626) | - | 54 | ||||||||
|
|
|||||||||||||||
Net Income Attributable to Stepan | ||||||||||||||||
Company | $ 15,439 | $ 13,179 | + | 17 | $ 79,396 | $ 71,976 | + | 10 | ||||||||
|
|
|||||||||||||||
Net Income Per Common Share | ||||||||||||||||
Attributable to Stepan Company | ||||||||||||||||
Basic | $0.71 | $0.63 | + | 13 | $3.71 | $3.44 | + | 8 | ||||||||
Diluted | $0.68 | $0.59 | + | 15 | $3.49 | $3.21 | + | 9 | ||||||||
Shares Used to Compute Net | ||||||||||||||||
Income Per Common Share | ||||||||||||||||
Attributable to Stepan Company | ||||||||||||||||
Basic | 21,777 | 20,836 | + | 5 | 21,273 | 20,726 | + | 3 | ||||||||
Diluted | 22,804 | 22,572 | + | 1 | 22,730 | 22,440 | + | 1 |
7
Table II |
Deferred Compensation Plan |
The full effect of the deferred compensation plan on quarterly pretax income was $4.1 million of expense versus expense of $3.5 million last year. The accounting for the deferred compensation plan results in operating income when the price of Stepan Company common stock or mutual funds held in the plan fall and expense when they rise. The Company also recognizes the change in value of mutual funds as investment income or loss. The quarter end market prices of Stepan Company common stock are as follows:
2012 | 2011 | |||||||||||||||
|
|
|
|
|
|
|||||||||||
12/31 | 9/30 | 6/30 | 3/31 | 12/31 | 9/30 | 6/30 | 3/31 | |||||||||
Stepan Company | $55.54 | $48.06 | $47.09 | $43.90 | $40.08 | $33.59 | $35.45 | $36.25 | ||||||||
The deferred compensation expense income statement impact is summarized below: | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31 | December 31 | |||||||||||||||
|
|
|
|
|||||||||||||
($ in thousands) | 2012 | 2011 | 2012 | 2011 | ||||||||||||
Deferred Compensation | ||||||||||||||||
Administrative (Expense) | $ (3,990) | $ (4,240) | $ (10,251) | $ (1,529) | ||||||||||||
Other, net Mutual Fund Gain | (156) | 705 | 1,480 | 38 | ||||||||||||
Total Pretax | $ (4,146) | $ (3,535) | $ (8,771) | $ (1,491) | ||||||||||||
Total After Tax | $ (2,571) | $ (2,192) | $ (5,438) | $ (923) | ||||||||||||
Reconciliation of non-GAAP net income: | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31 | December 31 | |||||||||||||||
|
|
|
|
|||||||||||||
($ in thousands) | 2012 | 2011 | 2012 | 2011 | ||||||||||||
Net income excluding deferred | ||||||||||||||||
compensation | $ 18,010 | $ 15,371 | $84,834 | $72,900 | ||||||||||||
Deferred compensation plan (expense) | (2,571) | (2,192) | (5,438) | (923) | ||||||||||||
|
|
|||||||||||||||
Net income as reported | $ 15,439 | $ 13,179 | $79,396 | $71,976 | ||||||||||||
Reconciliation of non-GAAP EPS: | ||||||||||||||||
Three Months Ended | Twelve Months Ended | |||||||||||||||
December 31 | December 31 | |||||||||||||||
|
|
|
|
|||||||||||||
2012 | 2011 | 2012 | 2011 | |||||||||||||
Earnings per diluted share excluding | ||||||||||||||||
deferred compensation | $0.79 | $0.68 | $3.73 | $3.25 | ||||||||||||
Deferred compensation plan (expense) | (0.11) | (0.09) | (0.24) | (0.04) | ||||||||||||
|
|
|
|
|||||||||||||
Earnings per diluted share | $0.68 | $0.59 | $3.49 | $3.21 |
The Company believes that certain non-GAAP measures, when presented in conjunction with comparable GAAP (Generally Accepted Accounting Principles) measures, are useful because that information is an appropriate measure for evaluating the Companys operating performance. Internally, the Company uses this non-GAAP information as an indicator of business performance, and evaluates managements effectiveness with specific reference to these indicators. These measures should be considered in addition to, neither a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
8
Table III |
Effects of Foreign Currency Translation
The Companys foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e., because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results). Below is a table that presents the impact that foreign currency translation had on the changes in consolidated net sales and various income line items for the quarter and year ending December 31, 2012:
(Decrease) Due | ||||||||
Three Months | Increase | to Foreign | ||||||
($ in millions) | Ended December 31 | (Decrease) | Translation | |||||
2012 | 2011 | |||||||
Net Sales | $ 427.3 | $ 444.2 | $(16.9) | (2.1) | ||||
Gross Profit | 70.1 | 60.1 | 10.0 | (0.5) | ||||
Operating Income | 24.6 | 21.1 | 3.5 | (0.3) | ||||
Pretax Income | 21.2 | 18.2 | 3.0 | (0.3) | ||||
(Decrease) Due | ||||||||
Twelve Months | Increase | to Foreign | ||||||
($ in millions) | Ended December 31 | (Decrease) | Translation | |||||
2012 | 2011 | |||||||
Net Sales | $1,803.7 | $1,843.1 | ($39.4) | (39.6) | ||||
Gross Profit | 291.6 | 255.6 | 36.0 | (5.2) | ||||
Operating Income | 128.7 | 118.5 | 10.2 | (2.7) | ||||
Pretax Income | 115.7 | 104.9 | 10.8 | (2.6) |
9
Table IV |
Stepan Company Consolidated Balance Sheets December 31, 2012 and December 31, 2011
2012 | 2011 | |||
December 31 | December 31 | |||
ASSETS | ||||
Current Assets | $523,078 | $479,742 | ||
Property, Plant & Equipment, Net | 422,022 | 383,983 | ||
Other Assets | 40,378 | 37,393 | ||
Total Assets | $985,478 | $901,118 | ||
LIABILITIES AND STOCKHOLDERS EQUITY | ||||
Current Liabilities | $247,167 | $233,226 | ||
Deferred Income Taxes | 9,200 | 8,644 | ||
Long-term Debt | 149,564 | 164,967 | ||
Other Non-current Liabilities | 98,667 | 88,816 | ||
Total Stepan Company Stockholders Equity | 478,985 | 401,211 | ||
Noncontrolling Interest | 1,895 | 4,254 | ||
Total Liabilities and Stockholders Equity | $985,478 | $901,118 |
10